Bisoxatin
Identification
- Generic Name
- Bisoxatin
- DrugBank Accession Number
- DB09219
- Background
Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine 1. It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 333.343
Monoisotopic: 333.100107967 - Chemical Formula
- C20H15NO4
- Synonyms
- Bisoxatin
Pharmacology
- Indication
For use in the treatment of constipation in the absence of bowel obstruction and for surgical preparation of the colon 1.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Bisoxatin is a stimulant laxative which increases peristalsis and inhibits the absorbtion of water and ions in the intestine 1. This increases the water content of the feces and increases its movement through the intestine.
- Mechanism of action
The precise mechanism of the bisoxatin's stimulant effect and inhibition of water and ion movement is unknown.
- Absorption
Once dissociated from acetate, some bisoxatin is absorbed with a Tmax of 4 h 1.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Absorbed compound is metabolized to bisoxatin glucuronide 1.
- Route of elimination
Primarily excreted in the feces 48-72 h after administration as the free parent compound with a small amount remaining as the acetate salt 1. Bisoxatin glucuronide and a trace amount of parent compound are eliminated in the urine.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Acetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Bisoxatin. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Wylaxine (Omega Pharma Belgium)
Categories
- ATC Codes
- A06AB09 — Bisoxatin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Benzoxazinones / Benzomorpholines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Secondary carboxylic acid amides / Lactams / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds show 3 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / Alkyl aryl ether / Aromatic heteropolycyclic compound / Azacycle / Benzomorpholine / Benzoxazine / Benzoxazinone / Carbonyl group / Carboxamide group / Carboxylic acid derivative show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 7C75N0L7FP
- CAS number
- 17692-24-9
- InChI Key
- BPKUDUSVDVLOPY-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H15NO4/c22-15-9-5-13(6-10-15)20(14-7-11-16(23)12-8-14)19(24)21-17-3-1-2-4-18(17)25-20/h1-12,22-23H,(H,21,24)
- IUPAC Name
- 2,2-bis(4-hydroxyphenyl)-3,4-dihydro-2H-1,4-benzoxazin-3-one
- SMILES
- OC1=CC=C(C=C1)C1(OC2=CC=CC=C2NC1=O)C1=CC=C(O)C=C1
References
- General References
- FAMPH: Bisoxatin Summary of Product Characteristics [Link]
- External Links
- PubChem Compound
- 28689
- PubChem Substance
- 310265126
- ChemSpider
- 26684
- ChEBI
- 135955
- ZINC
- ZINC000002017901
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Bisoxatin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0201 mg/mL ALOGPS logP 3.61 ALOGPS logP 3.75 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 9.15 Chemaxon pKa (Strongest Basic) -5 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 78.79 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 93.92 m3·mol-1 Chemaxon Polarizability 34.26 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0002-3719000000-80675a9182cffee4ad90 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-30d33f37042e8ea068bc Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-d5f2947e5fe49ff143cd Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-000x-5319000000-55df61f7eee5cad4e82a Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000x-0194000000-13500052d1c28b141f23 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0ab9-0920000000-86171fc2578284a00541 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0297-9250000000-304d25c6b8f29a0de70c Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 192.8098169 predictedDarkChem Lite v0.1.0 [M-H]- 178.32356 predictedDeepCCS 1.0 (2019) [M+H]+ 193.1179169 predictedDarkChem Lite v0.1.0 [M+H]+ 180.68156 predictedDeepCCS 1.0 (2019) [M+Na]+ 192.4811169 predictedDarkChem Lite v0.1.0 [M+Na]+ 187.68132 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2015 21:47 / Updated at February 21, 2021 18:52